Key result
Excess adiposity and metabolic dysfunction are linked to myocardial structural and functional abnormalities through multiple systemic and local mechanisms, rather than a single obesity-related trait.
Answers are grounded in this paper and cite their sources.
This editorial highlights the complex, multi-mechanistic relationship between excess adiposity, metabolic dysfunction, and myocardial mechanics, emphasizing that obesity-associated myocardial dysfunction is likely driven by a combination of systemic and local factors rather than a single trait.
HomeCirculation: Heart FailureVol. 10, No. 5The Heavy Heart Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBThe Heavy HeartMetabolic Mechanisms and Myocardial Mechanics Amanda R. Vest, MBBS, MPH and Ayan R. Patel, MD Amanda R. VestAmanda R. Vest From the Division of Cardiology, Tufts Medical Center, Boston, MA. and Ayan R. PatelAyan R. Patel From the Division of Cardiology, Tufts Medical Center, Boston, MA. Originally published11 May 2017https://doi.org/10.1161/CIRCHEARTFAILURE.117.004092Circulation: Heart Failure. 2017;10:e004092Obesity is an independent risk factor for the development of left ventricular hypertrophy (LVH) and heart failure (HF) and, in particular, HF with preserved ejection fraction.1,2 The pathways from excess adiposity to abnormal myocardial structure and function, and then onwards to clinically overt HF, remain incompletely defined. Obesity is associated with a range of hemodynamic adaptations, including increased stroke volume, heart rate, sympathetic activity, and cardiac output, and an increase in left ventricular mass to accommodate the increased wall stress. Consequently, most obese individuals have normal or hyperdynamic left ventricular systolic function.3 Diastolic dysfunction may be detectable in as many as 57% of obese individuals (body mass index [BMI] ≥30 kg/m2) aged >50 years4; the proportion of obese individuals with systolic dysfunction is less clear, and the proposition of an obesity cardiomyopathy has been controversial. In this issue of Circulation: Heart Failure, Ho et al5 sought to examine the link between obesity-related metabolic traits and subclinical alterations in systolic myocardial mechanics detected by strain echocardiography.See Article by Ho et alWhether it is the obesity per se, the associated metabolic syndrome, or dysfunctional adipokine signaling that lead to myocardial dysfunction and HF has been a source of much investigation. It seems that abnormalities of myocardial structure and function start early in life. Obese children without additional cardiovascular risk factors show an association between excess adiposity and LVH, diastolic dysfunction, and abnormal circumferential strain, which may be independent of hypertension and insulin resistance.6,7 Among adults, obese individuals with greater insulin resistance and metabolic dysfunction show the greatest risk of HF development—for example, there is a greater risk of HF in normal-weight individuals with metabolic syndrome than in metabolically healthy obese individuals.8,9 Central adiposity, as indicated by an elevated waist circumference or waist-to-hip ratio, is strongly associated with insulin resistance, the metabolic syndrome, and abnormal adipokine signaling and is particularly predictive of incident HF.10 However, such studies have not resolved whether it is the insulin resistance, or components of the dysfunctional adipokine and inflammatory signaling, that impacts myocardial structure and function.Adiposopathy describes anatomic and functional abnormalities of adipose tissue that generate endocrine and immune activity with potential cardiovascular effects. According to this hypothesis, the amount of excess adiposity is not as important as its location and adipokine activity. Visceral adipose tissue, typically located centrally, is the most hormonally active fat compartment. Quantitative assessment of visceral versus subcutaneous fat deposits has linked the degree of visceral adiposity to left ventricular mass and left ventricular dysfunction.11 The secretion of visceral fat–derived adipokines, such as adiponectin, resistin, leptin, visatin, and apelin, and the inflammatory mediators tumor necrosis factor-α, interleukin-6, and angiotensinogen can exert both negative and positive effects on the cardiovascular system depending on the balance of substances secreted.For example, adiponectin promotes insulin sensitivity and normal endothelial function, is anti-inflammatory and antiatherogenic, and can protect against myocyte hypertrophy and ischemia-reperfusion injury. Adiponectin levels are usually reduced in obesity. Conversely, leptin is proinflammatory and proatherogenic and promotes LVH. In obese states unassociated with a rare leptin gene mutation, circulating leptin levels are high and soluble leptin receptor levels low, with functional leptin resistance.12 Higher circulating leptin has been associated with the risk of incident HF among 4080 older men without preexisting coronary heart disease, independent of BMI.13 However, in another elderly incident HF cohort, although higher circulating leptin was associated with a greater risk of HF, leptin did not provide incremental prognostic information beyond BMI.14 In the Framingham Offspring Study, resistin was associated with HF incidence, even after adjustment for BMI and insulin resistance.15 In another elderly cohort, resistin was strongly and equally associated with HF with preserved or reduced ejection fraction, even after controlling for imaging measures of adiposity.16Additional evidence supporting systemic metabolic mechanisms of myocardial dysfunction come from the bariatric surgery literature. Bariatric surgery can achieve marked weight loss and remission of diabetes mellitus, dyslipidemia, and hypertension, as well as regression of LVH and diastolic dysfunction.3 Significant changes in the key adipokines, inflammatory markers and incretins are seen in the weeks and months after Roux-en-Y gastric bypass or sleeve gastrectomy. Circulating levels of C-reactive protein and interleukin-6 fall in parallel with the improved insulin sensitivity that emerges almost immediately postoperatively. These metabolic improvements long precede the nadir of weight loss, which is typically seen 1 year after surgery. Circulating levels of adiponectin and leptin rapidly move toward normal, and the changes in leptin correlate with regression of LVH.17 Reversal of severe obesity via bariatric surgery was recently demonstrated to halve the rate of incident HF, as compared with a lifestyle intervention.18In addition to circulating adipokines that signal from central fat stores to the myocardium, it is possible that epicardial and perivascular adipose tissue fat may influence local myocardial metabolism and function. Epicardial fat volume is often increased in obese individuals and is susceptible to metabolic dysfunction. There are also marked abnormalities of myocardial substrate metabolism in obesity, with direct myocardial lipotoxicity being a candidate mediator of diastolic or systolic dysfunction. Obese individuals have elevated myocardial triglyceride content and impaired insulin-stimulated myocardial glucose uptake.19 After successful weight loss, the exaggerated myocardial uptake of dietary fatty acids decreases toward normal.20 Myocardial fatty acid and glucose utilization are tightly interlinked with, for example, inhibition of fatty acid oxidation by the presence of acetyl co-A for glycolysis, so that an increase in utilization of one substrate decreases the other. The improvements in myocardial energetics with weight loss seem to be closely linked to the improvements in myocardial diastolic function.21 In conclusion, there are multiple potential mechanistic pathways between excess adiposity and myocardial dysfunction, including the direct hemodynamic effects of obesity; systemic adipokine signaling from dysfunctional visceral adipose tissue; paracrine epicardial and perivascular adipose tissue signaling; abnormal myocardial substrate utilization; and myocardial lipotoxicity.The current report from Ho et al examines the relationship between myocardial systolic deformation and central adiposity, insulin resistance, and circulating levels of C-reactive protein, adiponectin, leptin, and soluble leptin receptor. This study provides additional insight into the complexity of the relationship between metabolic traits and alterations in cardiac mechanics in a large cohort. The observation that various components of metabolic dysfunction are associated with differing patterns of myocardial mechanics is intriguing, although caution must be exercised in interpreting the physiological significance of associations with the secondary radial strain parameters; for example, the discrepancies in the results for associations between cardiometabolic traits and radial strain obtained from the apical versus short axis views highlight the concern about the reliability of these particular parameters. While it is important to emphasize that the relationship between alterations in myocardial mechanics and the development of HF in obesity remains unknown, the results of the study by Ho et al provide support for the concept that myocardial dysfunction associated with obesity is likely mediated by multiple mechanisms collectively, rather than a single obesity-related trait. Taken together with previous clinical observations regarding the heterogeneity of myocardial response to obesity, we might envisage a scenario where the overall balance of metabolic mediators secreted from adipose tissue could drive changes in myocardial structure, metabolism, and function toward predominantly diastolic versus systolic failure.Such a hypothesis, accounting for the interactions of multiple mediators rather than focusing on single adipokine signals would be useful in explaining the markedly heterogeneous myocardial response to obesity. Ventricular diastolic or systolic dysfunction is not universally present in obese individuals, and when it does occur, there is variable clinical expression ranging from asymptomatic to exercise-induced myocardial dysfunction to end-stage clinical HF. Even when myocardial fatty infiltration is present, it does not necessarily result in left ventricular dysfunction or clinical disease. More detailed characterization of (1) the location and metabolic activity of adipose tissue, (2) the nature and extent of myocardial structural, metabolic and functional abnormalities, and (3) the presence and extent of HF symptoms may permit grouping into distinct obesity–myocardial phenotypes. It is already appreciated that BMI alone is too imprecise a measure to adequately reveal obesity–myocardial interactions. Now we must also recognize that focusing on a single circulating adipokine or inflammatory marker may give an imprecise picture of the myocardial response to obesity. By understanding the changes in the totality of this metabolic milieu, we may unlock an opportunity to understand the variable expression of the "heavy heart" along the spectrum of subclinical to clinically overt diastolic and systolic dysfunction.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to Amanda R. Vest, MBBS, MPH, 800 Washington St, Boston, MA 02111. E-mail: [email protected]References1. Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, Levy D. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction.Circ Heart Fail. 2013; 6:279–286. doi: 10.1161/CIRCHEARTFAILURE.112.972828.LinkGoogle Scholar2. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure.N Engl J Med. 2002; 347:305–313. doi: 10.1056/NEJMoa020245.CrossrefMedlineGoogle Scholar3. Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB. Bariatric surgery and cardiovascular outcomes: a systematic review.Heart. 2012; 98:1763–1777. doi: 10.1136/heartjnl-2012-301778.CrossrefMedlineGoogle Scholar4. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, Di Tullio MR. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort.J Am Coll Cardiol. 2011; 57:1368–1374. doi: 10.1016/j.jacc.2010.10.042.CrossrefMedlineGoogle Scholar5. Ho JE, McCabe EL, Wang TJ, Larson MG, Levy D, Tsao C, Aragam J, Mitchell GF, Benjamin EJ, Vasan RS, Cheng S. Cardiometabolic traits and systolic mechanics in the community.Circ Heart Fail. 2017; 10:e003536. doi: 10.1161/CIRCHEARTFAILURE.116.003536.LinkGoogle Scholar6. Van Putte-Katier N, Rooman RP, Haas L, Verhulst SL, Desager KN, Ramet J, Suys BE. Early cardiac abnormalities in obese children: importance of obesity per se versus associated cardiovascular risk factors.Pediatr Res. 2008; 64:205–209. doi: 10.1203/PDR.0b013e318176182b.CrossrefMedlineGoogle Scholar7. Saltijeral A, Isla LP, Pérez-Rodríguez O, Rueda S, Fernandez-Golfin C, Almeria C, Rodrigo JL, Gorissen W, Rementeria J, Marcos-Alberca P, Macaya C, Zamorano J. Early myocardial deformation changes associated to isolated obesity: a study based on 3D-wall motion tracking analysis.Obesity (Silver Spring). 2011; 19:2268–2273. doi: 10.1038/oby.2011.157.CrossrefMedlineGoogle Scholar8. Wang J, Sarnola K, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J. The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns.Atherosclerosis. 2010; 210:237–242. doi: 10.1016/j.atherosclerosis.2009.10.042.CrossrefMedlineGoogle Scholar9. Voulgari C, Tentolouris N, Dilaveris P, Tousoulis D, Katsilambros N, Stefanadis C. Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals.J Am Coll Cardiol. 2011; 58:1343–1350. doi: 10.1016/j.jacc.2011.04.047.CrossrefMedlineGoogle Scholar10. Aune D, Sen A, Norat T, Janszky I, Romundstad P, Tonstad S, Vatten LJ. Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies.Circulation. 2016; 133:639–649. doi: 10.1161/CIRCULATIONAHA.115.016801.LinkGoogle Scholar11. Abbasi SA, Hundley WG, Bluemke DA, Jerosch-Herold M, Blankstein R, Petersen SE, Rider OJ, Lima JA, Allison MA, Murthy VL, Shah RV. Visceral adiposity and left ventricular remodeling: The Multi-Ethnic Study of Atherosclerosis.Nutr Metab Cardiovasc Dis. 2015; 25:667–676. doi: 10.1016/j.numecd.2015.03.016.CrossrefMedlineGoogle Scholar12. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease.J Am Coll Cardiol. 2008; 52:1201–1210. doi: 10.1016/j.jacc.2008.05.060.CrossrefMedlineGoogle Scholar13. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Obesity and risk of incident heart failure in older men with and without pre-existing coronary heart disease: does leptin have a role?J Am Coll Cardiol. 2011; 58:1870–1877. doi: 10.1016/j.jacc.2011.06.057.CrossrefMedlineGoogle Scholar14. Lieb W, Sullivan LM, Harris TB, Roubenoff R, Benjamin EJ, Levy D, Fox CS, Wang TJ, Wilson PW, Kannel WB, Vasan RS. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals.Diabetes Care. 2009; 32:612–616. doi: 10.2337/dc08-1596.CrossrefMedlineGoogle Scholar15. Frankel DS, Vasan RS, D'Agostino RB, Benjamin EJ, Levy D, Wang TJ, Meigs JB. Resistin, adiponectin, and risk of heart failure the Framingham offspring study.J Am Coll Cardiol. 2009; 53:754–762. doi: 10.1016/j.jacc.2008.07.073.CrossrefMedlineGoogle Scholar16. Butler J, Kalogeropoulos A, Georgiopoulou V, de Rekeneire N, Rodondi N, Smith AL, Hoffmann U, Kanaya A, Newman AB, Kritchevsky SB, Vasan RS, Wilson PW, Harris TB; Health ABC Study. Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study.Arterioscler Thromb Vasc Biol. 2009; 29:1144–1149. doi: 10.1161/ATVBAHA.109.186783.LinkGoogle Scholar17. Perego L, Pizzocri P, Corradi D, Maisano F, Paganelli M, Fiorina P, Barbieri M, Morabito A, Paolisso G, Folli F, Pontiroli AE. Circulating leptin correlates with left ventricular mass in morbid (grade III) obesity before and after weight loss induced by bariatric surgery: a potential role for leptin in mediating human left ventricular hypertrophy.J Clin Endocrinol Metab. 2005; 90:4087–4093. doi: 10.1210/jc.2004-1963.CrossrefMedlineGoogle Scholar18. Sundström J, Bruze G, Ottosson J, Marcus C, Näslund I, Neovius M. Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment.Circulation. 2017; 135:1577–1585. doi: 10.1161/CIRCULATIONAHA.116.025629.LinkGoogle Scholar19. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women.Circulation. 2004; 109:2191–2196. doi: 10.1161/01.CIR.0000127959.28627.F8.LinkGoogle Scholar20. Labbé SM, Noll C, Grenier-Larouche T, Kunach M, Bouffard L, Phoenix S, Guérin B, Baillargeon JP, Langlois MF, Turcotte EE, Carpentier AC. Improved cardiac function and dietary fatty acid metabolism after modest weight loss in subjects with impaired glucose tolerance.Am J Physiol Endocrinol Metab. 2014; 306:E1388–E1396. doi: 10.1152/ajpendo.00638.2013.CrossrefMedlineGoogle Scholar21. Lin CH, Kurup S, Herrero P, Schechtman KB, Eagon JC, Klein S, Dávila-Román VG, Stein RI, Dorn GW, Gropler RJ, Waggoner AD, Peterson LR. Myocardial oxygen consumption change predicts left ventricular relaxation improvement in obese humans after weight loss.Obesity (Silver Spring). 2011; 19:1804–1812. doi: 10.1038/oby.2011.186.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Brand A, Bathe M, Hübscher A, Baldenhofer G, Hättasch R, Seeland U, Oertelt-Prigione S, Rücke M, Regitz-Zagrosek V, Stangl K, Dreger H, Stangl V and Knebel F (2018) Normative reference data, determinants, and clinical implications of right atrial reservoir function in women assessed by 2D speckle-tracking echocardiography, Echocardiography, 10.1111/echo.14092, 35:10, (1542-1549), Online publication date: 1-Oct-2018. May 2017Vol 10, Issue 5 Advertisement Article InformationMetrics © 2017 American Heart Association, Inc.https://doi.org/10.1161/CIRCHEARTFAILURE.117.004092PMID: 28495954 Originally publishedMay 11, 2017 Keywordsleft ventricular hypertrophyheart failurestrainobesityepidemiologyEditorialsPDF download Advertisement SubjectsEchocardiographyMetabolic SyndromeObesity
No takes yet. Share an insight, caveat, or question.
Vest et al. (2017) conducted an editorial in Obesity and Heart Failure. Excess adiposity and metabolic dysfunction are linked to myocardial structural and functional abnormalities through multiple systemic and local mechanisms, rather than a single obesity-related trait.
Synapse has enriched 10 related papers. Consider them for comparative context: